Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 42


In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9.

Mi J, Ray P, Liu J, Kuan CT, Xu J, Hsu D, Sullenger BA, White RR, Clary BM.

Mol Ther Nucleic Acids. 2016 Apr 26;5:e315. doi: 10.1038/mtna.2016.27.


Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.

Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD.

Invest New Drugs. 2016 Apr;34(2):149-58. doi: 10.1007/s10637-015-0318-3. Epub 2016 Jan 4.


EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.

Clin Cancer Res. 2014 Feb 15;20(4):972-84. doi: 10.1158/1078-0432.CCR-13-0709. Epub 2013 Dec 18.


Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.

Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, Månsson JE, Pastan IH, Bigner DD.

MAbs. 2013 Sep-Oct;5(5):748-62. doi: 10.4161/mabs.25860. Epub 2013 Jul 25.


Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.

Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.

Clin Cancer Res. 2013 Sep 1;19(17):4717-27. doi: 10.1158/1078-0432.CCR-12-3891. Epub 2013 Jul 15.


Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH.

J Immunol Methods. 2013 Sep 30;395(1-2):14-20. doi: 10.1016/j.jim.2013.06.003. Epub 2013 Jun 24.


Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):270-5. doi: 10.1073/pnas.1219817110. Epub 2012 Dec 17.


Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.

Int J Cancer. 2013 May 15;132(10):2339-48. doi: 10.1002/ijc.27919. Epub 2012 Nov 23.


Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.

Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.


Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, Bigner DD.

Nucl Med Biol. 2012 Jan;39(1):23-34. doi: 10.1016/j.nucmedbio.2011.06.005. Epub 2011 Sep 29.


Bispecific antibodies engage T cells for antitumor immunotherapy.

Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH.

Expert Opin Biol Ther. 2011 Jul;11(7):843-53. doi: 10.1517/14712598.2011.572874. Epub 2011 Mar 30. Review.


Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis.

Kuan CT, Chang J, Mansson JE, Li J, Pegram C, Fredman P, McLendon RE, Bigner DD.

BMC Dev Biol. 2010 Nov 18;10:114. doi: 10.1186/1471-213X-10-114.


Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR.

Nucl Med Biol. 2010 Oct;37(7):785-94. doi: 10.1016/j.nucmedbio.2010.03.010.


Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.

Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE 2nd, Pastan I, Bigner DD.

Int J Cancer. 2011 Jul 1;129(1):111-21. doi: 10.1002/ijc.25645. Epub 2010 Nov 3.


MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Kuan CT, Wakiya K, Herndon JE 2nd, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD.

BMC Cancer. 2010 Sep 1;10:468. doi: 10.1186/1471-2407-10-468.


Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.

Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR.

Oncogene. 2010 Sep 16;29(37):5135-45. doi: 10.1038/onc.2009.279. Epub 2010 Jul 12.


Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD.

Hybridoma (Larchmt). 2009 Dec;28(6):389-403. doi: 10.1089/hyb.2009.0049.


GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.

Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, Månsson JE, Bigner DD.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):750-5. doi: 10.1016/j.bbrc.2009.11.132. Epub 2009 Nov 26.


Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.

Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD.

Int J Cancer. 2010 Aug 1;127(3):598-611. doi: 10.1002/ijc.25062.


A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.

Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):547-51. doi: 10.1016/j.bbrc.2009.10.001. Epub 2009 Oct 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk